Not Signed In - ViroPharma Announces Positive Data From Phase 1b Combination Study Of HCV-796 And Pegylated Interferon In Hepatitis C Patients
Tue, 29 Aug 2006 07:00 AM EST
... ViroPharma Incorporated today announced preliminary data from a Phase 1b study ofHCV-796, a unique, orally dosed hepatitis C virus (HCV) polymeraseinhibitor being co-developed with Wyeth Pharmaceuticals, a division ofWyeth (NYSE: WYE). [click link for full article] ...
Related Topics
- Data & Statistics
- Hepatitis C
- Data Analysis
- Hepatitis B
- National Data
- Ribavirin and Interferon alfa-2b, recombinant
- Hepatitis A
- Interferon Gamma-1b Injection
- Viral Load
- Hepatitis
- Interferon Beta-1b Injection
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Autoimmune Hepatitis
- Mining
- Combination Vaccines
- Peginterferon alfa-2a
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
email this page
print this page
bookmark this page
feedback on this page
